- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring a Recently Approved Therapy for Demodex
An expert ophthalmologist discusses a medication which targets enzymes in the Demodex mite, given over a six-week course.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of an Insights involving Neda Shamie, MD.
There is a recently FDA-approved treatment for Demodex blepharitis called Xdemvy (lotilaner ophthalmic solution 0.25%). Xdemvy targets and paralyzes an enzyme only found in the Demodexmite, effectively eradicating the mite. It is used twice daily for 6 weeks to cover the full life cycle. Over the treatment course, thedrug shows an impressively effective response in not just controlling but eradicating Demodexinfestation. It is a fast, highly effective, and reliable treatment.
In studies and clinical practice, Xdemvy eyedrops have not had significant adverse effects. Most patients find it soothing to the ocular surface with no adverse reactions. About 10% of study patients described a burning sensation upon drop installation. Less than 2% developed chalazion or hordeolum while on treatment. Overallit is very safe, highly effective and welltolerated, with a 6-week, twice-daily course, which supports good compliance. Many patients report completing the full course, motivated to control their disease.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More
